Cures Within Reach

04/17/2026

Clinical trial funding available! We've opened our 2026 AI Validation RFP to fund clinical trials in any disease area that validate AI predictions of disease-drug repurposing matches. LOI submission deadline: June 26. Have questions? Join one of our AI Validation RFP info sessions! RFP details:
- Investigator-initiated Phase I/IIA clinical trials in any unsolved disease
- Led by a PI from a nonprofit academic / research institution based anywhere in the world
- Using already approved drugs, biologics and eligible cellular/gene therapies, whether on or off-patent
- Submission must include AI model data as part of required preclinical supporting evidence
- More information and how to start a submission are available at https://bit.ly/cwrrfps
Thanks to partners Biohub and Lyda Hill Philanthropies.

04/14/2026

During , we are proud to now fund an open label crossover pilot trial “Using a Wearable Leg Stimulation Device to Improve Mobility of Veterans with Parkinson’s” led by Dr. Kalea Colletta of Hines VA Hospital.

https://www.cureswithinreach.org/2025/12/17/using-a-wearable-leg-stimulation-device-to-improve-mobility-of-veterans-with-parkinsons/

04/10/2026

Apply for funding in our 4 open RFPs including Veterans and AI Validation. Learn about our new Chicago trials. Read the The Chronicle of Philanthropy feature. Meet our April Researcher Spotlight: Dr. Roch Christian Johnson of Université d'Abomey-Calavi in Benin - all in our April newsletter - found here: https://bit.ly/4e9gtyA.

04/09/2026

Chicago is a major hub for clinical research, and we’re growing the happening across the city with our funding of 5 new trials at Chicago-based research institutions. Focused on areas where patients urgently need better options. By testing already approved therapies, our approach helps move potential treatments to patients faster and at a lower cost. With the support of partners including the Searle Funds at The Chicago Community Trust, we are also expanding our investment in early-stage investigators, critical as traditional medical research funding is becoming harder to secure. https://www.cureswithinreach.org/2026/04/09/press-release-cwr-approves-five-clinical-trials-at-chicago-institutions/
Lurie Children's Hospital
The University of Chicago
Hines VA Hospital

03/17/2026

During Awareness Month, we are proud to now be funding an ongoing Phase IIA trial “Treating with Stellate Ganglion Block via TMS Neuromodulation” led by Dr. Yosef Berlow at Providence VA Medical Center and Ocean State Research Institute.
VA Providence Healthcare System

There is an urgent need for new therapeutic approaches to treating patients with PTSD, as current treatment options often fail to alleviate symptoms for many. This Phase IIA, multi-arm, placebo-controlled trial is testing a neuromodulation method, applying a transcranial magnetic stimulation (TMS) d...

03/13/2026

Apply for clinical trial funding! Our 2026 LMIC, Chicago and Veterans RFPs are open for submissions. Read about these and our 6 recently selected AI Validation clinical trials plus meet our March Researcher Spotlight: Dr. Lixin Zhang of Dent Neurologic Institute in our March newsletter: https://bit.ly/3Nmqbm9

03/05/2026

Clinical trial funding available for : apply by April 10 to our open RFP. We will fund up to 9 clinical trials testing off-patent, approved therapies led by under-resourced researchers and clinicians in . Budgets of up to US$70,000 and a preference for impacting high disease burden. More details at https://bit.ly/cwrrfps. Help spread the word!

02/28/2026

On , we celebrate patients and caregivers. Our selection of 6 new clinical trials to validate AI-driven drug-disease predictions, including 3 trials focused on rare/ultra-rare diseases, represents a pivotal step in turning powerful computational predictions into real treatments for patients. By combining AI insights with real-world clinical validation, these trials aim to accelerate access to therapies and bring new hope to patients who have long had none. Because in rare diseases, speed matters.

https://www.cureswithinreach.org/2026/02/25/press-release-cures-within-reach-selected-three-clinical-trials-in-rare-ultrarare/

Biohub Channeling Hope Foundation Jeremy Tanner Tyler Beck National Center for Advancing Translational Sciences Lyda Hill Philanthropies Nicole Small National Organization for Rare Disorders, Inc. (NORD) Global Genes EURORDIS-Rare Diseases Europe Canadian Organization for Rare Disorders Rare Disease Day

02/25/2026

Ahead of Rare Disease Day, we’re taking an important step forward for the community. We have selected 6 new clinical trials to validate AI-driven drug-disease predictions, including 3 trials focused on rare/ultra-rare diseases, which represents a pivotal step in turning powerful computational predictions into real treatments for patients. By combining AI insights with real-world clinical validation, these trials aim to accelerate access to therapies and bring new hope to patients who have long had none. Because in rare diseases, speed matters.

https://www.cureswithinreach.org/2026/02/25/press-release-cures-within-reach-selected-three-clinical-trials-in-rare-ultrarare/
Biohub
Channeling Hope Foundation
Jeremy Tanner
Tyler Beck
National Center for Advancing Translational Sciences
Lyda Hill Philanthropies
Nicole Small

02/19/2026

Our funding is now supporting an ongoing Phase II trial led by Dr. Chinwe Chukwudi at University of of Nigeria: Treating Cutaneous Leishmaniasis with a Topical Antiseptic in Nigeria. Read more here: https://www.cureswithinreach.org/2026/01/26/treating-cutaneous-leishmaniasis-with-a-topical-antiseptic-in-nigeria/

Leishmaniasis is a neglected tropical disease caused by parasites transmitted through sandfly bites, affecting 1 to 2 million people and leading to thousands of deaths each year. Treatment remains a challenge worldwide due to variability of parasite species across regions and limited efficacy/access...

02/17/2026

Spread the word about our clinical trial funding! Our 2026 LMIC and Chicago-focused RFPs are now accepting LOI submissions. Read about these and other RFPs coming soon plus meet our Feb Researcher Spotlight: Dr. Austin Wesevich of The University of Chicago in our Feb newsletter: https://bit.ly/4cw4uu3​​

02/11/2026

Exciting News! We selected 7 new LMIC-based clinical repurposing trials in 2025 to advance therapies for patients facing high disease burdens using generic, available medicines. With support from Coefficient Giving, these trials are led by researchers in Bangladesh, India, Kenya, Nigeria and Tanzania plus funding for engaging community organizations. This brings our LMIC portfolio to 26 trials with more to be selected in 2026 from our now open funding opportunity RFP, all to strengthen local research capacity and accelerating equitable access to treatment. Learn more: https://www.cureswithinreach.org/2026/02/11/press-release-cwr-selected-seven-more-clinical-trials-to-address-factors-that-lead-to-high-disease-burden-in-low-and-lower-middle-income-countries/